ANNX — Annexin Pharmaceuticals AB (publ) Cashflow Statement
0.000.00%
Last trade - 00:00
- SEK91.15m
- SEK69.74m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -28.3 | -43.7 | -51.2 | -40.7 | -44.2 |
Non-Cash Items | 4.22 | 4.47 | 4.47 | 0.193 | 0.193 |
Other Non-Cash Items | |||||
Changes in Working Capital | -1.62 | 0.066 | 1.74 | -0.634 | 0.58 |
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -25.7 | -39.2 | -45 | -41.2 | -43.4 |
Capital Expenditures | 0 | — | 0 | 0 | 0 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | -0.096 | 0 | -0.26 | 0.096 |
Change in Net Investments | |||||
Cash from Investing Activities | 0 | -0.096 | 0 | -0.26 | 0.096 |
Financing Cash Flow Items | 0 | -7.62 | -10.3 | -0.047 | -2.9 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.229 | 53.2 | 76.4 | 23.1 | 33.6 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -26 | 13.9 | 31.3 | -18.4 | -9.7 |